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ABSTRACT 
Impaired cognitive function is a frequent consequence of multiple sclerosis (MS). It 
negatively affects vocational status, treatment adherence, physical independence, competence 
in activities of daily life, rehabilitation potential, driving safety and quality of life. All papers 
in this thesis concern cognitive function in relapsing-remitting MS (RRMS), with emphasis 
on clinical and neurophysiological predictors, moderating factors and the effect of 
natalizumab (NZ) treatment. 
I. The aim of this paper was to identify the strongest clinical predictors for cognitive 
impairment in RRMS patients. Patients with RRMS (n=72) and healthy control subjects 
(n=89) underwent comprehensive cognitive testing and clinical assessment. Physical 
disability (EDSS), fatigue (FSS), somatic and non-somatic components of depression (BDI-S 
and BDI-NS), disease progression rate (MSSS), and presence of psychotropic medication 
were included in the analysis. Patients had a mean EDSS of 2.7 and disease duration of 9.3 
years. Depression and fatigue estimates were significantly higher in patients than in control 
subjects (p<0.0001). Cognitive impairment had a prevalence of 30.5% in patients affecting 
preferentially executive functions, attention and processing speed. EDSS, FSS, BDI-NS and 
BDI-S were significantly correlated with several cognitive domains and global cognitive 
function in patients. In regression models, cognitive performance was best predicted by BDI-
NS alone or in combination with EDSS. Exclusion of patients with any psychotropic 
medication did not influence the main findings. 
II. The objective of paper II was to explore if cognitive impairment in RRMS is associated 
with abnormal neural function, and if there is evidence of neural compensatory mechanisms. 
The study population described in paper I underwent event-related brain potential (ERP) 
recordings with visual and auditory choice reaction tasks. Patients had increased visual P300 
amplitude frontally. Auditory and visual P300 amplitude were normal in other brain areas, 
and response time (RT) was normal. P300 latency was normal except for an increase in 
auditory latency occipitally. Cognitive performance correlated positively with visual and 
auditory parietal P300 amplitude in patients (p<0.0001 and p=0.009, respectively) but not in 
controls. Global cognitive score had a significantly stronger correlation (negative) with RT in 
patients than in controls (intergroup difference for visual stimulation p=0.015, and for 
auditory p=0.050). Notably, these associations were not an epiphenomenon of the cognitive 
impairment in patients, because parietal P300 amplitude and RT were normal. We concluded 
that patients with low P300 amplitude and long RT were more often cognitively impaired. 
III. The aim of paper III was to distinguish different mechanisms for cognitive reserve in 
RRMS. Thus, we wished to test the cognitive reserve hypothesis in the present study 
population. This hypothesis predicts that high premorbid intelligence, as may be estimated 
from years of education and vocabulary knowledge, attenuates the effects of disease burden 
on cognitive functioning. In this analysis, the normal effects of premorbid intelligence on the 
test scores need to be accounted for. Thus we compared the strength of the correlation 
between premorbid intelligence and cognitive performance in patients and controls, 
respectively. Contrary to the prediction, premorbid intelligence had no stronger effect on 
cognition in patients than in controls. This finding contrasted against the results in paper II 
where P300 amplitude and RT did have stronger effect on cognitive function in patients than 
in controls, i.e. showed features of a reserve against cognitive impairment in patients. The 
strongest neurophysiological (visual P300 amplitude and RT) and clinical (EDSS and BDI-
NS) predictors of cognitive function were studied in a hierarchical linear regression model. 
P300 amplitude and RT explained 34% of the variance in global cognitive function 
(p<0.001). EDSS and BDI-NS added significantly to explained variance, and the final model 
accounted for 44% (p<0.001) of the variation. In a separate analysis, we found that the effects 
of P300 and RT on cognitive function were not moderated by premorbid intelligence. 
IV. The objective of paper IV was to evaluate the cognitive effects of NZ treatment, 
compared to patients on stable first-line treatment and healthy control subjects. Fifteen MS 
patients (MS-NZ) underwent cognitive testing when starting NZ treatment and were tested 
again after one year. They were compared with fifteen MS patients on stable interferon beta 
therapy (MS-C) and twelve healthy control subjects (HC) who also were tested twice with an 
interval of one year. The effects of NZ on levels of self-reported depression, fatigue, daytime 
sleepiness and perceived health were also examined. MS patients (MS-NZ and MS-C) had 
significantly lower baseline cognitive performance compared to HC (global score, p=0.002). 
At follow-up, both MS-NZ and MS-C had improved significantly in four and five cognitive 
domains, respectively, and in global cognitive score (p=0.013 and p<0.001, respectively). HC 
improved significantly in three cognitive domains but not in global score. A regression 
analysis showed that participants with lower baseline scores had a significantly greater 
improvement, compared to those with a better initial performance (p=0.021). There were no 
significant changes in depression, fatigue, daytime sleepiness or perceived health in MS-NZ 
or MS-C. 
 
 
  
Conclusions 
Symptoms of depression, especially non-somatic symptoms, and level of physical disability 
are the most important clinical risk factors for cognitive impairment in RRMS patients. 
General factors such as ERP amplitude and RT are limiting for cognitive function in RRMS 
because P300 amplitude and RT have significantly stronger associations with cognitive 
performance in patients compared to HC. 
High P300 and fast RT reflect a physiological reserve which may be the strongest moderator 
of cognitive impairment in RRMS. In contrast, premorbid intelligence does not constitute a 
cognitive reserve in RRMS patients. 
The observed increase in frontal P300 amplitude suggests activation of compensatory 
networks. 
There is no evidence of a beneficial effect on cognitive performance after one year of NZ 
treatment. Retest effects are significant and are important to recognize in studies of cognitive 
performance. 
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1 INTRODUCTION 
1.1 MULTIPLE SCLEROSIS 
Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system (CNS) 
primarily affecting persons between 20-40 years of age. MS is a leading cause of neurologic 
disability among young adults in the developed world. Worldwide, there are more than 2.5 
million MS patients [1]. In Sweden, the incidence and prevalence of MS has been estimated 
to 10.2 and 188.9/100 000/year, respectively, resulting in approximately 17 500 patients, with 
a female to male ratio of 2.35:1 [2, 3].  
Pathologically, MS is characterized by widespread lesions, or plaques, in the brain and spinal 
cord, causing a variable degree of inflammation, gliosis and neurodegeneration. The 
pathogenesis involves both the innate and adaptive immune system leading to widespread 
focal lymphocytic infiltration. The exact cause of MS is yet unknown. A complex interaction 
of genetic and environmental factors which triggers an abnormal immune response is 
suggested [4]. Inflammatory lesions primarily affect the myelin sheath causing inhibition of 
axonal transmission which eventually leads to irreversible axonal loss. MS is mainly regarded 
as a demyelinating disease of the white matter in the brain, but involvement of the cortical 
grey matter is also an important element and not restricted to the progressive stages of the 
disease [5].  
The diagnosis of MS rests on a combination of disease history, clinical signs and defined 
paraclinical findings [6]. Depending on the disease course, MS patients are separated into 
three subgroups: relapsing-remitting MS (RRMS), secondary progressive MS (SPMS) and 
primary progressive MS (PPMS) [7]. The disease typically presents as RRMS where 
neurological symptoms evolve sub-acutely and then persist for days or weeks before they 
gradually remit, however, often leaving some permanent residual neurological symptoms. 
Neurological deficits depend on the location of the lesions within the CNS but are usually 
motor, sensory or visual, or a combination of all. The relapse rate is highly variable between 
patients. The degree of residual symptoms tends to increase with reoccurring relapses. After a 
variable period of time, most RRMS patients enter a progressive phase where physical 
disability gradually increases without clear relapses (SPMS). In PPMS, the disease is 
progressive from start. Importantly, in SPMS and PPMS, neuroinflammation is less 
pronounced and disease progression is driven mainly by other, less well characterized, 
mechanisms [4].  
During the last 20 years, an increasing number of effective drugs for MS have become 
available. Disease modifying treatment (DMT) has the ability to reduce the frequency of 
clinical relapses, the accumulation of neurological disability and the radiological signs of 
disease activity [8]. To date, the use of DMT is restricted to patients with RRMS. The list of 
currently approved DMTs in Sweden includes interferon beta (1a and 1b), glatiramer acetat, 
natalizumab, fingolimod, dimethyl fumarate, teriflunamide and alemtuzumab [9]. Overall, the 
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basic principle of action for DMTs is inhibition of lymphocyte activity, proliferation and/or 
migration, thus affecting only the inflammatory component of the disease [8]. 
1.2 COGNITIVE IMPAIRMENT IN MS 
Besides motor, sensory and visual deficits, MS leads to mood and cognitive disturbances. In 
the last decades, research in MS has increased remarkably. However, at the beginning of this 
research project, the amount of research dedicated to the cognitive field of MS had not 
increased equally [10]. Cognitive impairment in MS is frequent, affecting up to 65% of 
patients in cross sectional studies [14, 15]. It is detectable at all stages and subtypes of the 
disease [16], including patients with clinically isolated syndrome (CIS) [17]. In RRMS, the 
prevalence of cognitive dysfunction is estimated to 22-40% [16, 18]. Patients with SPMS or 
PPMS tend to have an even higher frequency of cognitive impairment [19]. Cognitive 
impairment in MS usually persists and worsens over time [14, 20]. The need for a deeper 
understanding of MS-associated cognitive impairment is stressed by its detrimental effects on 
many activities of daily life such as physical independence, employment, coping, medication 
adherence, symptom management, rehabilitation potential and driving safety [11]. Self-
perception of cognitive performance in MS patients is unreliable and not predictive of 
objective cognitive functioning [12, 13] and formal testing is therefore necessary. 
Cognition is not a uniform entity, but includes many aspects of complex mental functions. 
Various domains of cognitive functioning can be affected in MS. Reduced performance has 
been demonstrated in information processing speed, attention, executive functions and 
memory. Verbal fluency, but not core language abilities, is often reduced in MS. Impaired 
information processing speed and learning and memory are often considered the major 
cognitive deficits in MS [21].  
While there is an overall consensus about the general profile and importance of cognitive 
impairment in MS, there is less consensus on clinical risk factors. Previous studies have 
found a modest or moderate association between cognitive performance and level of physical 
disability [18, 22, 23], but this relationship is likely to be less pronounced or lacking when the 
level of physical disability is lower [10]. Cognitive impairment may exist independently of 
physical disability [24]. A consistent finding in previous studies has been a weak or absent 
correlation between duration of MS and cognitive impairment [15, 18, 21, 23]. However, an 
association is likely to emerge when disease duration exceeds 10 years [10]. The speed of 
clinical disease progression can be measured with the Multiple Sclerosis Severity Score 
(MSSS) which is an algorithm based on disease duration and level of physical disability [25]. 
To our knowledge, the MSSS has not previously been evaluated regarding its possible 
relationship with cognitive performance.  
The relationship between depression in MS and cognitive impairment has not been clear [21], 
but an association has been demonstrated in adequately powered studies [26] and primarily 
between depression and the cognitive domains of information processing speed and executive 
functions [27, 28]. Commonly used scales for depression include items rating presence and 
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severity of somatic symptoms which can be confounded by disease related symptoms in 
clinical samples such as MS patients. In these depression scales, somatic and non-somatic 
items can usually be separated but most prior studies have not made this distinction. 
However, in studies where cognitive performance was correlated with the separate 
components of depression, a stronger association was reported for the non-somatic symptoms 
[29, 30]. 
Fatigue is a common symptom in patients and an association with decreased information 
processing speed has been reported [31]. However, several other studies did not find 
subjective fatigue to be associated with cognitive impairment [32, 33].  
A concomitant use of CNS-active psychotropic medication against depression, fatigue, pain 
and insomnia is often present in MS patients. These drugs may have effects, negative or 
positive, on cognitive performance. In studies on cognitive functioning in MS patients, 
information regarding the use of psychotropic medication is frequently lacking. 
1.3 IMAGING AND COGNITIVE IMPAIRMENT IN MS 
Magnetic resonance imaging (MRI) is the most commonly used paraclinical tool to 
investigate MS pathology and to monitor disease evolution. Cognitive deficits in MS has 
been related to a disconnection syndrome caused by involvement of white matter tracts [34]. 
However, most studies have shown a modest or moderate association between visible lesions 
and cognitive impairment in MS [35]. The overall effect of lesion volume on cognitive 
impairment is limited and lesion assessment alone is not considered adequate to assess and 
monitor cognitive function in MS patients [35].  
With disease progression, white matter abnormalities change from predominantly focal and 
periventricular to more subtle and diffuse. Such changes are accompanied by an increase in 
the extent of demyelination within the grey matter [36]. Some grey matter atrophy is found 
early in the disease course but becomes prominent in SPMS [37] and the rate of brain atrophy 
is considered to accelerate around conversion from RRMS to SPMS [38]. As compared to 
assessment of lesions, measures of global or regional brain atrophy have a more robust 
association with cognitive performance in MS [39, 40]. However, quantification of brain 
atrophy has so far not been available in clinical practice. The presence of diffuse damage in 
the white and grey matter, as identified with experimental and more advanced MRI 
techniques, are likely to be important for the cognitive impairment [35].  
Brain cortical activation can be visualized with functional MRI (fMRI). Several fMRI studies 
have indicated that cognitive task performance is associated with increased or altered cortical 
activation patterns in patients with MS [41]. RRMS patients with normal performance in a 
test of processing speed and working memory activated larger frontal cortical areas compared 
to healthy control (HC) subjects. In contrast, this increased activity was less pronounced in 
RRMS patients with a lower cognitive performance [41].  
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1.4 MODERATING FACTORS OF COGNITIVE IMPAIRMENT 
As described, the relationship between measures of disease burden and cognitive outcomes is 
incomplete and the amount of explained variance in statistical models remains moderate [35, 
42]. This phenomenon is not restricted to MS but is seen in other neurological diseases also. 
For example, higher levels of premorbid intelligence and educational attainment may be 
factors associated with a slower deterioration in Alzheimer´s disease (AD). This has been 
attributed to a larger ‘cognitive reserve’, attenuating the effects of the disease process on 
cognitive functioning [43]. More generally, cognitive reserve can be defined as a brain 
structure or function that optimizes the individual cognitive performance in the presence of 
brain pathology or injury. Because direct measurement of cognitive reserve is not available, 
proxy or surrogate variables are used. Premorbid intelligence, as estimated from years of 
education or performance in vocabulary tests, is tested as a moderating factor together with 
other predictors of cognitive outcomes [44, 45]. Cross-sectional studies in populations of 
mixed sub-groups of MS have reported a moderating effect of premorbid intelligence on the 
relationship between MRI variables of disease burden and cognitive impairment [46-49]. The 
effect of cognitive reserve can be assessed in a correlation analysis between premorbid 
intelligence and cognitive test performance. To support the cognitive reserve hypothesis this 
correlation needs to be significantly stronger among patients than in healthy individuals [50, 
51] (Fig. 1). Previous studies have reported such a finding in MS patients [52, 53]. Cognitive 
reserve in MS is however still a novel field of research, and the need for replication has been 
stressed [54]. 
It is important to recognize the pervasive effects of education on cognitive test performance 
in normal healthy individuals [55]. Premorbid intelligence may be of clinical importance even 
if it does not retard the speed of cognitive decline. Let us assume that there is a certain level 
where the cognitive decline becomes critical for work abilities and activities of daily life (Fig. 
2).  For individuals with high premorbid intelligence at disease onset, it takes longer to reach 
this critical level than for those with low premorbid intelligence. This difference may be 
thought of as a ‘reserve’ but is not meant with ‘cognitive reserve’. 
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Fig. 1. Schematic illustration of the cognitive reserve hypothesis. The correlation between 
premorbid intelligence (e.g. educational attainment) and cognitive performance should be 
significantly stronger in the clinical sample (black solid line) than in the normal healthy 
sample (black interrupted line). 
 
Fig. 2. Schematic illustration of the cognitive reserve hypothesis in a longitudinal analysis. 
The decline in cognitive performance should be slower in patients with high premorbid 
intelligence (red solid line) than in patients with low premorbid intelligence (blue solid line). 
Note that even in the absence of this phenomenon, patients with high premorbid intelligence 
(red interrupted line) will reach a level of clinical impairment (grey solid line) at a later stage 
and thus still benefit from a higher premorbid intelligence. 
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1.5 NEUROPHYSIOLOGICAL ASSESSMENT OF BRAIN FUNCTION 
1.5.1 Event-related potentials 
All mental functions are mediated through highly complex neuronal activity within the CNS. 
This is associated with electrical activity causing voltage fluctuations on the scalp which can 
be recorded in the electroencephalogram (EEG). Specific fluctuations can be elicited in the 
EEG in response to standardized discrimination tasks involving sensory stimuli (events). 
Event-related potentials (ERPs) can be elicited when a subject differentiates between two 
different stimuli and responds to the target with a button press. The stimuli are usually 
auditory (different sounds) or visual (different visual patterns on a screen). The tasks are not 
difficult to perform but require the participant´s attention. ERP recordings are non-invasive 
and have an excellent temporal but moderate spatial resolution [56]. 
Different testing paradigms exist. In the odd-ball design, the subject is instructed to respond 
only to a predefined infrequent target stimulus in a train of frequent non-target stimuli. In a 
choice-reaction task design, the subject responds to both of the different stimuli, with a left or 
right hand button press. Each stimulus (visual or auditory) generates a small electrical signal 
which is recorded in the EEG. In order to distinguish this signal from the background 
spontaneous EEG activity, it is necessary to perform an averaging of repeated events. The 
ERPs appear as a series of positive and negative voltage fluctuations (components), which 
can be quantified with regard to amplitude and latency [56].  
Three main models have been proposed for the mechanisms how ERPs are generated [57]. 
According to the evoked model, ERPs are created when silent neurons are activated by the 
stimulus. Another model suggests a resetting mechanism where neurons with ongoing 
oscillatory activity undergo sudden transition to a specific phase due to the stimulus. A third 
model proposes that the stimulus induces high frequency oscillations which in turn are 
correlated with low frequency activity and a baseline shift. The subsequent signal averaging 
cancels the high frequency component, leaving the baseline shifts in the EEG. 
ERPs are classified in a standardized manner after polarity (N, negative or P, positive) and 
approximate peak latency. The most widely studied ERP is the large positively deflecting 
component peaking around 300 ms after the stimulus event and before the motor response 
(P300). P300 is generated over widespread bilateral cortical regions and dominates over 
centro-parietal scalp regions [58, 59]. There is general agreement that P300 is not a unitary 
phenomenon but rather represents distributed neural activity that comprises several 
functionally distinct and mutually overlapping subcomponents. E.g., in easy tasks 
subcomponents of the P300 add together, whereas in more difficult conditions they diverge 
leading to a reduced amplitude [60]. Furthermore, a more frontally dominating component 
can be elicited depending on the nature of the stimulus paradigm [61]. The P300 component 
is commonly regarded as the neural origin of the cognitive processes related to volitional 
detection behavior and the P300 amplitude increases in proportion to the amount of 
attentional capacity invested in the event categorization [60]. The amplitude of P300 is also 
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dependent on the nature and presentation of the given stimulus. Character and appearance 
probability (such as inter-stimulus interval) of the targets influence the amplitude [61]. P300 
latency is considered to measure the time required to detect and evaluate a given stimulus 
[62]. Any brain disorder affecting cognitive processes may reduce amplitude and increase 
latency of the P300 [63]. 
Early ERP components, appearing <200 ms after a stimulus, are commonly regarded as 
sensory or exogenous in nature with no relation to cognitive processes. However, an 
association between early components and cognitive function has been described in diabetes 
mellitus [64]. 
1.5.2 Event-related potentials and MS 
Previous research with ERP assessments in MS patients is heterogeneous due to 
discrepancies in sample size, clinical characteristics, cognitive testing and EEG electrode 
numbers [65, 66]. Most previous ERP-studies have included mixed samples of MS-patients, 
including both patients with RRMS and those with progressive subtypes of the disease, 
making inferences or generalizations regarding subgroups of MS difficult. These studies have 
generally reported reduced amplitude and increased latency of the P300 component [65, 66]. 
Larger effects on P300 are seen in the SPMS and PPMS, compared to RRMS [67]. Some 
studies report normal P300 amplitudes in MS patients, despite reduced cognitive test 
performance [68, 69]. In CIS patients with reduced cognitive performance, P300 amplitude 
and latency are normal [70].  
Few studies have combined MRI and ERP recordings in MS. P300 latency has been reported 
to be increased and to be correlated with MRI lesions [71]. In another study, P300 to auditory 
and visual stimuli were normal in three groups of MS patients stratified after degree and 
distribution of MRI lesions [72]. In MS, early ERP components were found to be both normal 
[69, 71] and abnormal [73-76]. 
1.5.3 Response time 
Performance in time-dependent cognitive tests is often reduced in MS patients. The response 
time (RT) of auditory and visual target detection can be assessed during ERP recordings but 
is frequently lacking in studies with MS patients. RT in ERP stimulation tasks has been 
reported to be slower [72, 75] or normal [77] but the studies differ with regard to MS patient 
characteristics and type and difficulty of stimuli. Fast RT is associated with better cognitive 
abilities in healthy individuals [78]. Similarly, a relationship between RT and measures of 
processing speed has been reported in RRMS patients [79]. They found that RT in choice 
reaction tasks was a more sensitive measure of impaired information processing in RRMS as 
compared to a simple RT task. 
1.6 TREATMENT OF COGNITIVE DYSFUNCTION IN MS 
There is no proven effective rehabilitation program or symptomatic treatment for MS-related 
cognitive dysfunction. Symptomatic drug treatment to ameliorate cognitive impairment in 
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MS patients has been investigated. A randomized clinical trial with donepezil (an acetyl 
cholinesterase inhibitor approved for AD) was negative [80]. Furthermore, the evidence from 
trials using central stimulants is weak or non-existing [81]. Many studies have reported some 
cognitive improvement in MS patients following cognitive rehabilitation programs. However, 
the evidence reported in the literature remains inconclusive, mainly due to methodological 
weaknesses [82, 83].  
All approved DMTs reduce the accumulation of brain damage as measured by MRI and thus 
should have the potential to slow or restore cognitive function in patients. However, data is 
not abundant regarding the specific effects of DMTs on cognitive functioning in MS. Most 
studies report an improvement or less deterioration in patients receiving DMTs. However, the 
interpretation of data in clinical trials with DMTs is complicated because cognitive 
performance is usually a secondary outcome measure and cognitive testing is often restricted 
to a single test [81]. Natalizumab (NZ) is one of the more potent DMTs available. Studies 
regarding its effect on cognitive outcome in RRMS have reported beneficial effects, however 
often lacking control groups [84-91].
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2 AIMS OF THE THESIS 
2.1 GENERAL AIM 
The general aim of this thesis was to identify clinical risk factors and neurophysiological 
correlates of cognitive impairment in RRMS patients, and to study the effect of NZ treatment 
on cognitive functioning. 
2.2 SPECIFIC AIMS 
The aim of paper I was to identify the strongest clinical risk factors for cognitive impairment 
in RRMS patients. Physical disability, depression and fatigue are known to be interrelated in 
MS and may all influence cognitive function. The comparison included the importance of the 
disease progression speed vs. physical disability, the somatic vs. non-somatic component of 
depression, and the possible confounding effect of psychotropic medication (e.g. 
antidepressants). 
The aim of paper II was to explore if cognitive impairment in RRMS patients is associated 
with abnormal neuronal function, if there is evidence of neural compensatory mechanisms 
and if the association between cognitive function and ERP variables is different in patients 
compared to HC subjects. 
The aim of paper III was to distinguish how different factors influence cognitive function in 
RRMS. In particular, we tested if cognitive impairment in RRMS is influenced by premorbid 
intelligence, how much of the variance in cognitive function is explained by clinical and 
neurophysiological predictors, and if the associations of P300 and RT with cognitive 
performance are moderated by premorbid intelligence. 
The aim of paper IV was to examine the effects of the first year of NZ treatment, compared 
with a control receiving standard DMT, on cognitive functioning in RRMS patients. A 
second objective was to study the effects on measures of depression, fatigue, daytime 
sleepiness and perceived health. 
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3 SUBJECTS AND METHODS 
3.1 SUBJECTS 
RRMS is the largest subgroup of MS and the only one in which DMTs are approved. The 
degree of cognitive impairment may vary depending on subgroup [19]. For these reasons, 
only RRMS patients were included in this research project. 
The thesis is based on the results from two sets of data. Dataset 1 (paper I, II and III) is a 
cross-sectional analysis including RRMS patients (n=72) and HC subjects (n=89). The 
patients were recruited at the Department of Neurology at the Karolinska University Hospital 
in Stockholm (Solna) between April 2006 and May 2011. The HC subjects were recruited 
randomly by the aid of the Swedish population registry (Statistiska centralbyrån).  
Dataset 2 (paper IV) is a longitudinal analysis including RRMS patients (n=30) and HC 
subjects (n=12), tested twice with an interval of one year. The participants in dataset 2 were 
recruited between February 2010 and June 2012. The HC subjects in paper IV were chosen 
from the HC subjects of dataset 1.  
3.2 CLINICAL INSTRUMENTS 
All patients and control subjects were clinically evaluated. The instruments used for the 
different groups are indicated in the list below. 
The Kurtzke Expanded Disability Status Scale (EDSS) [92] was used to assess physical 
disability in patients. This scale has been designed specifically for MS patients and is the 
most frequently and widely used scale to rate physical disability.  
Multiple Sclerosis Severity Score (MSSS) [25] was used to rate disease severity. The MSSS 
is an algorithm relating the score on EDSS with disease duration.  
Beck Depression Inventory (BDI) [93] was used to assess symptoms of depression in 
patients and HC subjects in all papers. BDI is a widely used self-report questionnaire for 
scoring depressive symptoms, and it is recommended for use in populations with MS [94, 
95]. The BDI score was also separated into its non-somatic (BDI-NS, items 1-13), and its 
somatic part (BDI-S, items 14-21). 
Center for Epidemiologic Studies - Depression (CES-D) [96] is a scale for self-assessment 
of depressive symptoms given to patients in paper IV, in addition to the BDI. CES-D is 
widely used and has good accuracy for predicting clinical depression in MS [97].  
Fatigue Severity Scale (FSS) was used for the assessment of subjective fatigue in patients 
and controls in all papers. The nine item FSS is the most widely used scale to rate fatigue in 
MS, showing high reliability, validity and internal consistency [98].  
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Fatigue Scale for Motor and Cognitive functions (FSMC) [99] is a scale for rating 
subjective fatigue and it is designed specifically for the use in MS patients. It was given to 
patients in paper IV.  
Epworth Sleepiness Scale (ESS) [100] was used to measure daytime sleepiness in patients in 
paper IV.  
Perceived health (PH) was evaluated with the first item from the Health Related Quality of 
Life Short Form (SF-12®) [101]. It was scored on a Likert scale (1 to 5) where 1 is 
“excellent” and 5 is “poor”. PH was evaluated in patients in paper IV. 
The scores from CES-D and FSMC may be divided and reported as four (CES-D) or two 
(FSMC) subscales [96, 99]. However, due to the limited sample size in paper IV and in order 
to reduce the number of comparisons, we included only the total scores. For the same 
reasons, only the total BDI score was reported in paper IV.  
The HC subjects in paper IV (n=12) had received the BDI and FSS at their first test session 
(dataset 1) but not the CES-D, FSMC, ESS and PH. Thus, they were only given the BDI and 
FSS at the second evaluation. 
3.3 COGNITIVE EXAMINATION 
Patients and controls underwent a comprehensive cognitive evaluation covering six cognitive 
domains (memory, verbal ability, attention, executive functions, visual perception and 
organization and processing speed). The included tests were available in Swedish and could 
be administered, after sufficient training, by a non-neuropsychologist. All participants were 
tested in a distraction-free and quiet environment. Several tests measure more than one 
cognitive ability and were thus included in more than one cognitive domain. The grouping of 
tests and subtests into cognitive domains was theoretical and decided after discussion among 
the authors of paper I (Table 1). The included tests are listed below. 
Benton Visual Retention Test (BVRT-5) (Form C, Administration A) [102]. The task is to 
memorize and reproduce visual patterns. Domains: memory, visual perception and 
organization. 
Rey Auditory Verbal Learning Test (RAVLT and RAVLT-recall) [103]. The task is to 
learn and recall a list of words. Domain: memory. 
Vocabulary from the Synonyms, Reasoning and Block Test, part 1 (SRB:1) [104, 105]. The 
task is to identify correct synonyms. Domain: verbal ability. In paper III, the SRB:1 is treated 
as a surrogate marker for premorbid intelligence [55]. 
Controlled Oral Word Association Test from the Delis-Kaplan Executive Function System 
(D-KEFS) [106]. The task is to verbally produce, in 60 sec, as many words as possible, 
beginning with a specific letter. Domains: verbal ability, executive functions, processing 
speed. 
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Color-Word Interference Test from D-KEFS [106]. The test consists of four timed subtests. 
Condition 1 (color naming), condition 2 (word reading), condition 3 (inhibition) and 
condition 4 (inhibition and switching). Domains: attention (Condition 1 and 2), executive 
functions (Condition 1, 2, 3 and 4). 
Trail Making Test from D-KEFS [106]. The test consists of five timed subtests. Condition 1 
(visual scanning), condition 2 (number sequencing), condition 3 (letter sequencing), condition 
4 (number-letter sequencing) and condition 5 (motor speed). Domains: attention (Condition 
1, 2, 3 and 5), executive functions (Condition 1, 2, 3, 4 and 5). 
Block Design Test from the Wechsler Adult Intelligence Scale - third edition (WAIS-III) 
[107]. The timed task is to reproduce patterns using a set of cubes. Domain: visual perception 
and organization. 
Digit Span Test (Forward and Backward) from WAIS-III [107]. The task is to verbally 
repeat, forward or backward, series of digits. Domains: attention (Forward, Backward and 
Total), executive functions (Backward). 
Digit Symbol Coding Test from WAIS-III [107]. The task is to fill in as many correct 
symbols as possible in 120 sec. Domains: visual perception and organization, processing 
speed. 
Symbol Search Test from WAIS-III [107]. The task is to correctly complete as many symbol 
comparisons as possible in 120 sec. Domains: visual perception and organization, processing 
speed. 
Additionally, premorbid verbal IQ was assessed by the Swedish Lexical Decision Test 
(SLDT) [108] in all HC subjects and in patients in paper IV. The total number of cognitive 
test scores was twenty. However, RAVLT and RAVLT-recall were not part of dataset 1 
because they were not initially included in the patients´ study protocol. Besides test grouping 
into domains, a global score was calculated and included in all papers. The total number of 
cognitive test sessions in the present thesis was 218. 
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Cognitive domain 
 
Cognitive tests 
 
Memory Benton Visual Retention Test     
Rey Auditory Verbal Learning Test 
Rey Auditory Verbal Learning Test – recall 
 
Verbal ability Controlled Oral Word Association Test 
Vocabulary Test 
 
Attention Color-Word Interference Test, condition 1 and 2 
Digit Span Test, Forward                         
Digit Span Test, Backward 
Digit Span Test, Total 
Trail Making Test, condition 1,2,3 and 5 
 
Executive functions Color-Word Interference Test, condition 1-4 
Controlled Oral Word Association Test 
Digit Span Test, Backward 
Trail Making Test, condition 1-5 
 
Visual perception and organization Benton Visual Retention Test 
Block Design Test 
Digit Symbol Coding Test 
Symbol Search Test 
 
Processing speed Controlled Oral Word Association Test 
Digit Symbol Coding Test 
Symbol Search Test 
 
Global score 
 
All tests, including subtests 
 
Table 1. Cognitive tests and cognitive domains  
 
3.4 NEUROPHYSIOLOGICAL INVESTIGATIONS 
3.4.1 Recordings 
All patients and HC subjects underwent a neurophysiological investigation which was 
conducted in a separately located EEG room, designated for research subjects, at the 
Department of Neurophysiology at the Karolinska University Hospital (Solna). The 
investigation was usually performed within a few days from the cognitive and clinical 
evaluations and in many cases it was performed on the same day. EEG was recorded with a 
23-channel EEG amplifier (Nervus Digital Equipment Cephalon, Copenhagen, Denmark). 
The EEG silver cap electrodes were placed over both hemispheres according to the 10–20 
International System. The participants first underwent a standardized resting EEG followed 
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by auditory and visual choice reaction tasks. The collected neurophysiological data were 
auditory and visual ERPs in the two modalities. 
The specific procedures regarding test-response epochs, recording reference, ground 
electrode, inter-stimulus intervals, eye movements monitoring, sampling rate, post processing 
of signals and artifact rejection are detailed in paper II. 
3.4.2 Auditory ERPs 
Auditory ERPs were recorded during an auditory choice reaction task where the participants 
were seated with their eyes closed and were instructed to press response keys with their left 
and right index finger upon hearing low and high pitch signals, respectively. The signals were 
delivered through a loud speaker device at 65 dB and with a duration of 100 ms. Auditory 
ERP data were obtained by averaging trials with low and high pitch, respectively. P300 was 
identified as the largest positive peak in the interval 200-500 ms. 
3.4.3 Visual ERPs 
Visual ERPs were recorded with a visual choice reaction task using Kanizsa images of an 
illusory square or a non-square (Fig. 3). The subjects were seated in front of a screen 
(distance 150 cm), and instructed to press with their right or left index finger, according to 
given instructions, when an illusory square or a non-square was presented. Visual ERP data 
were obtained by averaging trials with illusory squares and non-squares, respectively. P300 
was identified as the largest positive peak in the interval 200-500 ms. P150 was identified as 
the largest positive peak in the interval 130-200 ms. 
3.4.4 Response time 
Response time (RT) was measured simultaneously with the ERP recordings in the auditory 
and visual experiment, respectively. RT was recorded from the onset of the stimulus to the 
time for response (button press). RT data were obtained by averaging trials of auditory 
stimuli (to both auditory targets) and visual stimuli (to both visual targets), respectively. 
 
Fig. 3. Images for the visual choice reaction task. Kanizsa illusory square (left panel) and 
non-square (right panel). 
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3.5 CALCULATIONS AND STATISTICS 
3.5.1 Normalization 
The cognitive test scores were normalized (z-scored) in order to adjust for the normal effects 
of age, sex and education. First a linear regression model of the effects of age on each 
cognitive test score, respectively, was calculated in the HC subjects separately for men and 
women. The residuals were then used to study the normal effect of education (years in school 
and higher education) in a second linear regression model and a final set of residuals was 
obtained. 
The regression lines obtained in the healthy control group for each test score, respectively, 
were used on the patient data to adjust for the effects of age separately for men and women 
and education, and the final residuals were obtained for each subject and test. Z-scores were 
calculated by dividing the final residuals with the standard deviation (S.D.) of the final 
residuals in the healthy controls. In this way the tests scores obtained the same weight and the 
cognitive domain scores could be calculated from the mean scores of the included tests. For 
each participant, a global score was constructed as the average of the z-scores obtained for all 
tests. 
ERP variables and RT were normalized to adjust for the normal effects of age and sex, 
following the same linear regression procedures described for the cognitive scores. Mean 
ERP parameter values were calculated for illusory squares and non-squares, and for low and 
high pitch signals, respectively. These calculations resulted in z-scored parameter values in 
each electrode position. Similarly, RT parameter values were also z-scored. 
3.5.2 Missing data 
In dataset 1, missing or excluded cognitive data were replaced with the mean value for each 
score in patients and controls, respectively. In dataset 2, missing data were not replaced. Only 
complete data, with both a baseline and follow-up value, entered the paired t-test analysis. 
3.5.3 Group comparisons, correlations and regression analyses 
Values were given as mean ± S.D. Significance level was p<0.05.  Differences in means 
between groups were tested using t-test. Correlation analyses were performed with ranked 
data (Spearman´s correlation). Multiple regression analysis was performed with robust linear 
regression. Paper III includes both parametric and non-parametric correlations, as indicated. 
In paper IV, baseline group differences were analyzed with ANOVA or Chi-square test. 
Other group comparisons at baseline were made with t-test or with Wilcoxon rank sum test in 
case of non-normal distributed data. Paired t-test was used to analyze changes in data 
between the first and second examination. 
3.5.4 Multiple comparisons 
To reduce the number of comparisons, cognitive test results were only analyzed on domain 
levels and as a global cognitive score. The included regression analyses have primarily used 
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global score as the dependent variable. In paper I, only clinical variables with a significant 
effect on the global score were considered to be significant. In paper II the number of 
comparisons was reduced by grouping electrode positions in five brain regions: frontal (F3, 
F4, F7, F8, Fz, Fp1, Fp2 and Fpz), central (C3, C4 and Cz), parietal (P3, P4 and Pz), temporal 
(T3, T4, T5 and T6) and occipital (O1, O2 and Oz). In the correlation analyses between 
cognitive performance and ERP variables (amplitude and latency), electrode data from 
responses to both targets were analyzed together in the auditory and visual modality, 
respectively. The Bonferroni procedure was used to correct for multiple independent 
comparisons. In paper II, the cumulative binomial distribution was used for multiple 
dependent comparisons because simultaneously recorded EEG electrode data from different 
locations are not independent from each other [109]. 
3.6 ETHICAL CONSIDERATIONS 
All subjects were informed about the nature and purpose of the study before consenting to 
participate. The protocol was approved by the regional ethics committee (Regionala 
etikprövningsnämnden i Stockholm). The study was conducted in accordance with Good 
Clinical Practice guidelines and the principles of the Declaration of Helsinki. 
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4 RESULTS 
4.1 PAPER I 
Sundgren, M., Maurex, L., Wahlin, Å., Piehl, F. and Brismar, T. (2013) Cognitive 
impairment has a strong relation to nonsomatic symptoms of depression in relapsing-
remitting multiple sclerosis. Arch Clin Neuropsychol, 28(2), pp. 144-55. 
RRMS patients (n=72) and HC subjects (n=89) were evaluated with a large cognitive test 
battery and an extensive clinical assessment. The clinical variables of interest were disease 
duration, physical disability (EDSS), disease severity (MSSS), fatigue (FSS), depression 
(BDI, BDI-NS, BDI-S) and presence of psychotropic medication (e.g. antidepressants). There 
were no significant differences between patients and HC in age (mean 37.9 and 38.2, 
respectively) or years of education (mean 13.8 and 14.1, respectively). In patients, mean 
disease duration was 9.3 years, EDSS 2.7 and MSSS 4.1. As expected, patients had 
significantly more symptoms of depression and fatigue compared to HC (p<0.0001). In 
patients, 31.9% had a BDI score ≥ 10 indicating an increased risk of depression. Patients had 
a high level of subjective fatigue as 52.8% had an FSS score ≥ 5. 
Patients had significantly lower cognitive performance than control subjects (global score -
0.71, p<0.0001), affecting preferentially executive functions (-0.92), attention (-0.88), 
processing speed (-0.64), and visual perception and organization (-0.49). Cognitive 
impairment, defined as z-score < -1.5 in two or more cognitive domains, had a prevalence of 
30.5%. Cognitive performance in patients had significant negative correlations (non-
parametric) with several of the clinical variables. E.g., global cognitive score correlated with 
EDSS (r= -0.36), FSS (r= -0.31) and BDI-NS (r= -0.32). BDI-NS had stronger correlation 
with cognitive function than BDI-S. Disease duration and MSSS had no or little association 
with cognitive impairment. In HC subjects, cognitive performance did not correlate with FSS, 
BDI-NS or BDI-S. 
Importantly, several of the clinical variables associated with cognitive impairment in patients 
were intercorrelated. E.g., FSS was strongly correlated with EDSS, BDI-NS and BDI-S 
(p<0.0001). However, MSSS was not associated with FSS or BDI. Multiple regression 
analysis was performed to separate the effects of the clinical risk factors on cognitive function 
in patients. BDI-NS had stronger effect than other clinical variables, including BDI (total) 
and BDI-S, on cognitive function in all cognitive domains except verbal ability which had no 
significant predictor. The strongest relationship was between BDI-NS and executive 
functions (p<0.0001, adjusted r2= 0.223) and visual perception and organization (p<0.0001, 
adjusted r2= 0.198). Because depression may be secondary to the level of physical disability, 
we also performed a hierarchical regression analysis with EDSS as the first predictor. The 
model EDSS + BDI-NS resulted in higher adjusted r2 values, as compared to BDI-NS as the 
single predictor, in two cognitive domains. A model with EDSS + FSS was not significant in 
any cognitive domain. The regression analyses were repeated after exclusion of the RRMS 
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patients (n=25) that were receiving any psychotropic medication. However, the results were 
similar. 
4.2 PAPER II 
Sundgren, M., Nikulin, V. V., Maurex, L., Wahlin, Å., Piehl, F. and Brismar, T. (2015) 
P300 amplitude and response speed relate to preserved cognitive function in relapsing-
remitting multiple sclerosis. Clin Neurophysiol, 126(4), pp. 689-97. 
The study population described in paper I also underwent a neurophysiological investigation 
with ERP and RT assessments.  
Visual ERP 
Patients had a significant decrease in P150 amplitude and increase in P150 latency in the 
frontal region compared to controls. Patients displayed an increase in the P300 amplitude in 
the frontal region. E.g., in the Fpz electrode position the P300 amplitude (illusory square 
stimulation) was 8.9 ± 3.9 and 7.4 ± 3.3 µV in patients and controls, respectively (p<0.03). 
There were no differences between patients and controls regarding visual P300 amplitudes 
over any other brain region. Visual P300 latency was normal in patients.  
Auditory ERP 
The auditory P300 amplitude in response to both targets was normal in patients. There was a 
small but significant increase of auditory P300 latency in five, mainly occipital electrodes, in 
the low and high pitch stimulation (p=0.002). 
ERP and correlation with cognitive function 
The P150 amplitude and latency were not related to cognitive function in patients or control 
subjects. Contrary, there were consistent and significant correlations between cognitive 
function and P300 amplitude of both stimulation modalities in patients, in contrast to HC. In 
the linear correlation analysis between parietal visual P300 amplitude and global cognitive 
function the correlation coefficient was 0.44 (p<0.0001) in patients and 0.11 (n.s.) in controls. 
The strongest correlations (non-parametric) were seen for visual P300 in the parietal region 
(global score, r= 0.51, p<0.0001). P300 amplitude in other brain regions also had significant 
correlations with cognitive function, however less strong compared to the parietal P300. 
Auditory P300 amplitude correlated significantly with cognitive function in patients, albeit 
less so than visual. In HC subjects cognitive performance had a weak correlation (p<0.05) 
with visual P300 amplitude in the central region, but not in any other brain region and not 
with auditory P300 amplitude. The correlation analyses were repeated after exclusion of the 
patients with ongoing psychotropic medication (n=25), as specified in paper I, and the main 
findings were similar. 
Visual P300 latency in patients was not correlated with global score in patients and controls. 
Auditory P300 latency showed a positive correlation with three cognitive domains and the 
  19 
global score. This correlation was strongest in the central region (global score, r= 0.32, 
p=0.007). There was no correlation between auditory P300 latency and cognitive 
performance in controls. Our finding differed from the findings by Whelan et al. (2010) (see 
Errata) who described a negative correlation similar to the association between P300 latency 
and cognitive performance in dementia disorders where the latency is increased [63]. Our 
patients had normal auditory P300 latency in the central region. A possible explanation for 
the present finding is that the P300 often has multiple intra-component peaks in the normal 
interval [61]. A selective reduction of the later components would make the peak latency 
appear earlier.  
Visual and auditory RT 
Visual RT was 0.47 ± 0.08 and 0.45 ± 0.07 seconds and auditory RT was 0.62 ± 0.15 and 
0.60 ± 0.15 seconds, in patients and controls, respectively (n.s.).  
RT and correlation with cognitive function 
In linear correlation analysis, visual RT correlated significantly with global cognitive function 
in patients (-0.53, p<0.001) and in controls (-0.21, p<0.001). Auditory RT correlated 
significantly with global score in patients (-0.40, p<0.001) and in controls (-0.15, p=0.02). 
Similar to the results regarding P300, the intergroup difference in strength of correlation was 
significant.  
In patients, RT correlated significantly with the global score and all cognitive domains except 
memory (e.g., visual RT and global score, r= -0.52, p<0.001). In control subjects, significant 
correlations between RT and cognitive function were only present for visual RT, and the 
strongest association was observed for global score (-0.44, p<0.001). 
Subsequently we tested if the identified neurophysiological predictors were associated with 
the previously identified strongest clinical risk factors, but there were no significant 
correlations. 
4.3 PAPER III 
Sundgren, M., Wahlin, Å., Maurex, L. and Brismar, T. (2015) Event related potential 
and response time give evidence for a physiological reserve in cognitive functioning in 
relapsing-remitting multiple sclerosis. J Neurol Sci, 356(1-2), pp. 107-112. 
In paper III, we tested the cognitive reserve hypothesis in our sample of RRMS patients, 
using demographic data regarding participants´ formal education and level of vocabulary 
knowledge (SRB:1). The results were compared to the findings in paper II.  
Global cognitive function had a significant positive correlation with education in both 
patients (r= 0.102, p=0.007) and controls (r= 0.085, p=0.001). Similarly, global score 
correlated with vocabulary knowledge in patients (r= 0.29, p=0.004) and controls (r= 0.23, 
p=0.0003). The differences in strength of correlation between groups were however not 
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significant. Similarly, no intergroup differences were detected when the same correlation 
analyses were performed for each of the cognitive domains.  
The neurophysiological variables with the strongest association with global cognitive 
function in patients (visual RT and visual parietal P300 amplitude) and the strongest clinical 
predictors (EDSS and BDI-NS), were entered into a hierarchical multiple linear regression 
model where P300 and RT were Block 1, EDSS Block 2 and BDI-NS Block 3. The 
neurophysiological variables (Block 1) explained most of the variance (adjusted r2 = 0.335). 
The clinical predictors (Block 2 and 3) added significant variance, and the final model had an 
adjusted r2 of 0.444 (p<0.001). The regression analysis was repeated for the separate 
cognitive domains as the dependent variable, respectively. P300 and RT explained most of 
the variance (16-29%) in five of six domains. Memory was not predicted by P300 or RT or 
any of the clinical predictors. 
A possible moderating effect of premorbid intelligence on the association between P300/RT 
and cognitive function was tested in hierarchical regression models with global score and the 
six cognitive domains as dependent variables, respectively. Education (years) and vocabulary 
knowledge, respectively, were tested in Block 1 and P300 and RT, respectively, were tested 
in Block 2. The interactions education*P300, education*RT, vocabulary*P300 and 
vocabulary*RT were entered in Block 3, respectively. However, none of the interactions 
were found to be significant. 
4.4 PAPER IV 
Sundgren, M., Piehl, F., Wahlin, Å. and Brismar, T. Cognitive function did not improve 
after initiation of natalizumab treatment in relapsing-remitting multiple sclerosis. A 
prospective one-year dual control group study. Manuscript 
MS patients starting NZ (MS-NZ, n=15), MS controls with stable interferon beta therapy 
(MS-C, n=15) and healthy control subjects (HC, n=12) performed cognitive testing twice 
with an intertest interval of one year. The effects of NZ on levels of self-reported depression 
(BDI, CES-D), fatigue (FSS, FSMC), daytime sleepiness (ESS) and perceived health (PH) 
were also examined. There were no differences in age, sex, years of education or verbal IQ 
between the three groups. MS patients (MS-NZ and MS-C) had significantly lower baseline 
performance in all six cognitive domains and in global cognitive function compared to HC 
(global score, p=0.002). However, there were no significant baseline differences between 
MS-NZ and MS-C in cognitive performance. 
After one year, MS-NZ had improved significantly in memory (p=0.015), verbal ability 
(p=0.005), visual perception and organization (p=0.030), processing speed (p=0.003) and in 
global score (p=0.013). Similarly, MS-C improved significantly in memory (p=0.016), 
attention (p=0.030), executive function (p=0.016), visual perception and organization 
(p<0.001), processing speed (p<0.001) and global score (p<0.001). The HC group improved 
significantly in verbal ability (p=0.035), visual perception and organization (p=0.002) and 
processing speed (p=0.021), but not in the other three cognitive domains or in global 
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cognitive score. Due to these results, we hypothesized that the improvements could be 
secondary to a stronger retest effect in subjects with low baseline test performance. A 
regression analysis including baseline cognitive z-score and z-score change showed that 
participants with lower baseline scores had a significantly greater improvement at follow-up, 
compared to those with a better initial performance (Spearman´s rho -0.36, p=0.021). 
There was no significant change in depression, fatigue, daytime sleepiness or perceived 
health in MS-NZ or MS-C. HC subjects improved significantly in FSS (p=0.031). 
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5 CONCLUSIONS 
5.1 PAPER I 
Symptoms of depression, especially non-somatic symptoms, and level of physical disability 
are the most important clinical predictors of poor cognitive performance in RRMS patients. 
Fatigue is not a predictor when controlling for the effects of depression.  
Cognitive performance in RRMS is not related to MSSS or treatment with psychotropic 
medication.  
5.2 PAPER II AND III 
P300 and RT have stronger association with cognitive test performance in patients than in 
healthy controls. In specific, patients with larger P300 amplitude and faster RT had less 
cognitive impairment than those with lower P300 amplitude and RT. For this reason, P300 
amplitude and RT may be markers of a physiological reserve for cognitive functioning in 
RRMS.  
The increase in frontal P300 amplitude in patients may reflect compensatory mechanisms. 
The average P300 and RT showed only small differences between patients and controls, and 
for that reason they are not sensitive markers of brain dysfunction in RRMS. 
The proposed physiological reserve may be the strongest moderator of cognitive impairment 
in RRMS. Physiological reserve and clinical risk factors (physical disability and depression) 
explain a considerable amount of the variance in cognitive functioning in RRMS. In contrast, 
premorbid intelligence does not constitute a cognitive reserve in RRMS. 
5.3 PAPER IV 
There is no evidence of a beneficial effect of NZ treatment on cognitive functioning across 
one year. Significant improvement may be artificial and due to retest effects. 
Adequate control groups are essential when evaluating cognitive functioning in intervention 
trials in RRMS patients.  
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6 LIMITATIONS 
In dataset 1, memory function was restricted to the BVRT-5. It was not a sensitive test to 
detect impaired memory in patients, despite being a test of immediate visual memory which 
is considered to be vulnerable in MS [21]. In dataset 2, the memory domain also included the 
RAVLT and RAVLT-recall. In paper IV, patients had significantly lower performance in 
memory, compared to HC. 
Reduced eye saccadic initiation time and fine motor control of the hand may negatively 
interfere with the performance in written cognitive tests in MS, even in patients with low 
EDSS [110]. This could potentially have influenced performance in time-dependent tests. 
Depression was assessed with self-report scales. Thus, only subjective symptoms of 
depression were evaluated. A clinical diagnosis of depression would have required a deeper 
psychiatric interview using standardized major depression criteria. However, both BDI and 
CES-D have shown good diagnostic accuracy for depression in MS patients [97, 111]. 
Anxiety is related to depression but should be regarded as a separate psychological disorder. 
However, a separate measure of anxiety symptoms was not included among the clinical 
instruments.  
Disease burden was only assessed with clinical measures. MRI can provide additional 
information regarding lesion volume and brain atrophy. 
In Paper III, the cognitive reserve hypothesis was tested using years of education and 
vocabulary knowledge as proxies. However, there are other proposed surrogate markers of 
cognitive reserve that were not included, such as IQ or questionnaires grading the level of 
premorbid cognitive leisure activities. A test of verbal IQ (SLDT) was given to all healthy 
control subjects and MS patients entering the longitudinal study, but not to the majority of 
MS patients in dataset 1. 
In Paper IV, the relatively small numbers per group increased the risk of a type-II error 
regarding change in depression, fatigue, daytime sleepiness and perceived health.  
 
 
 
 
 
 
 
 24 
7 DISCUSSION AND FUTURE PROSPECTS 
7.1 CLINICAL RISK FACTORS 
We identified depression, especially non-somatic symptoms of depression, and physical 
disability as the strongest clinical predictors of cognitive impairment in RRMS. The 
separation of the somatic and non-somatic items in the BDI was justified because BDI-NS 
had a stronger association than BDI-S with cognitive function in patients. Subjective fatigue 
was common in patients but it was not a significant predictor for cognitive impairment when 
the effects of EDSS and BDI-NS were included in regression models. Notably, the means of 
EDSS and BDI were not high (2.7 and 8.8, respectively). In comparison, the level of fatigue 
was high as more than 50% of patients scored ≥5 in the FSS. Our finding that subjective 
fatigue is not a prominent predictor of cognitive impairment in MS is in agreement with 
previous reports [32, 33]. Similarly, we replicated the finding that disease duration is not 
associated with cognitive impairment in MS [15, 18, 21, 23]. Disease progression rate, as 
measured with MSSS was also not associated with cognitive impairment in patients. 
Furthermore, MSSS was not associated with depression or fatigue.  
In MS studies with cognitive outcome measures, the presence of CNS-active psychotropic 
drugs with potential effects on cognitive performance is frequently overlooked. However, 
psychotropic medication was not a confounding factor in our study. It is important to point 
out that the patients receiving psychotropic medication were heterogeneous with regard to 
indication, pharmaceutical substances, dosage and possible combinations of drugs. 
EDSS is regularly monitored in RRMS patients in contrast to symptoms of depression. The 
results point at the importance of evaluating depression, especially non-somatic mood 
symptoms, in RRMS patients with cognitive impairment. As a consequence, clinicians should 
consider the possibility of reduced cognitive function in clinically depressed patients. 
If there is an association between depressive symptoms and cognitive impairment in RRMS, 
would cognitive function improve if depression is successfully treated? This has not been 
sufficiently studied [27]. One controlled clinical study reported objective cognitive 
improvement parallel to improved mood [112], a finding that was not confirmed in a later 
study [113]. Despite the overall high prevalence of depression in persons with MS [114], 
there is a lack of well designed clinical trials for the treatment of depression in MS patients 
[115]. In future such studies, it should be considered that depressed but otherwise physically 
healthy individuals have an increased risk of cognitive impairment. Cognitive performance is 
not immediately restored after successful anti-depressive treatment [116, 117], not even when 
other abilities have returned to normal [118]. This issue relates to the topic regarding 
cognitive effects of concomitant psychotropic medication, discussed above. In our material, 
antidepressants were the most common psychotropic medication. 
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7.2 PHYSIOLOGICAL RESERVE 
A major finding was that cognitive performance in RRMS patients is strongly correlated with 
the strength of the electrical brain signal and time for response in choice reaction tasks. These 
correlations were absent or weaker in healthy individuals. Importantly, RT and parietal P300 
amplitude were normal in patients, and the correlations were not epiphenomena of reduced 
cognition. Additionally, P300 and RT were not correlated with EDSS. Similarly, in a 
previous study, auditory and visual P300 amplitude were normal and not significantly 
different between MS patients stratified according to level and distribution of MRI lesion 
volume [72]. The results suggest that RRMS patients rely more than healthy individuals on 
their level of brain attentional resources and behavioral response speed, for their cognitive 
performance. In other words, high P300 amplitude and fast RT may be protective against 
cognitive dysfunction in RRMS.  
In contrast, years of education and vocabulary knowledge influenced cognitive test 
performance equally in patients and healthy control subjects. Accordingly, premorbid 
intelligence did not constitute a cognitive reserve in patients. This is in variance with previous 
reports [52, 53]. We do not rule out that educational attainment and vocabulary knowledge 
attenuate the degree of cognitive impairment in MS patients with more advanced or severe 
disease [53]. 
A physiological reserve hypothesis can be formulated in the same way as the cognitive 
reserve hypothesis. Accordingly, patients should have a stronger correlation between the 
physiological reserve variable and cognitive function than healthy individuals. Our results 
show that P300 amplitude and RT, in contrast to premorbid intelligence, have this association 
with cognitive function in RRMS. We suggest that physiological reserve is as a cognition-
related neural buffer system that helps patients to compensate for the negative cognitive 
effects of MS pathology. Importantly, the physiological reserve explained as much as 34% of 
the variance in global cognitive function in RRMS. The combined effect of physiological 
reserve, physical disability (EDSS) and depression (BDI-NS) explained 44% of the variance.  
The description of a measurable physiological reserve in RRMS is a novel finding and may 
help identifying RRMS patients at increased risk of cognitive impairment. 
Physiological reserve has similarities with the definition of neural reserve proposed by Stern 
et al. [119]. Neural reserve represents the natural inter-individual variability in brain network 
efficiency and ability to perform a task. Thus, individuals with higher brain network 
efficiency may be better at coping with brain pathology.  
Neural compensation is another concept of cognitive reserve and refers to the process by 
which individuals suffering from brain pathology use different brain networks, or existing 
networks differently, to compensate for the disruption imposed by brain disease [44, 45]. In 
paper II we found a small but significant increase in frontal P300 amplitude in RRMS 
patients. This finding may correspond to an increased, and possibly compensatory, fMRI 
signal previously described in MS patients performing cognitive tasks [41, 120, 121]. 
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Previous studies have investigated the degree to which premorbid intelligence moderates the 
association between MRI indices of MS pathology and cognitive impairment [47-49]. The 
proposed physiological reserve should be tested similarly. Does the level of P300 amplitude 
and RT moderate the relationship between brain atrophy (or lesion load) and cognitive 
function in RRMS? Ideally, a physiological reserve hypothesis should be tested in a 
longitudinal study of sufficient length. Does high P300 amplitude and short RT reduce the 
risk of cognitive decline associated with MS? Or conversely, are patients with a lower 
physiological reserve at higher risk for cognitive impairment? Identification of patients with 
increased risk of cognitive dysfunction has recently been highlighted as an important 
challenge in MS [35]. MS typically begins at an earlier age than other common CNS 
disorders. Other concurrent dementing medical conditions are rare at this age and normal age-
related cognitive decline is not yet large, which facilitates such studies. 
7.3 FUTURE INTERVENTION STUDIES 
In the present papers we have compared the findings in the patients with control subjects. In 
paper IV, it was shown that after one year, NZ therapy did not improve cognitive function as 
compared with the control group of other MS patients. Presumably, the increased test 
performance in both MS groups was artificial and due to retest effects that were stronger in 
patients with a lower baseline performance. The results underscore the importance of 
including control groups when evaluating cognitive outcomes in intervention trials. Learning 
or retest effects are seen in several cognitive domains, are largest in young adults, and may be 
significant also after many years [122]. Retest effects are not restricted to healthy individuals 
as they have been described in a variety of clinical samples including MS-patients [123-125]. 
Uncontrolled studies on cognitive function have therefore limited value. Besides the need for 
control groups, several methods for attenuating or eliminating retest effects have been 
proposed, such as alternate forms of tests, standardized massed practice and creation of 
reliable change indices. However, there is no consensus on the best method [126]. Contrary to 
common belief, alternate forms do not eliminate retest effects [127] and may, if forms are not 
psychometrically equivalent, introduce irrelevant variance [126]. Including only healthy 
individuals as controls is not likely to be sufficient, since retest effects cannot be assumed to 
be equal in magnitude in healthy and clinical samples or in individuals across different ages 
[122, 128]. Indeed, paper IV showed that the retest effect was larger in patients with a lower 
baseline performance. Regardless these constraints, these aspects need to be addressed in 
future studies, especially intervention studies with symptomatic drug treatment or cognitive 
rehabilitation programs. Targeted enrollment of MS patients with a lower cognitive reserve, 
thus at increased risk of developing cognitive impairment, has been suggested [129].  
Regarding the cognitive outcome of DMT interventions, comparable non-intervention patient 
control groups can not readily be created, for obvious ethical reasons. If DMT mainly limits 
progression, rather than restoring function, a future study on cognitive function would 
probably need to extend over several years because the natural rate of progression of 
cognitive dysfunction may be slow [14]. Considering the difficulties constructing well 
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designed controlled clinical DMT trials with cognitive outcomes, are there acceptable 
alternatives? One option may be large scale observational data, which could be achieved 
through MS-registries [130]. However, currently only a single cognitive test (symbol digit 
modalities test, SDMT) is regularly monitored, and additional tests may be needed to better 
cover the spectrum of cognitive deficits. A three test screening battery, the Brief International 
Cognitive Assessment for Multiple Sclerosis (BICAMS), has been proposed to monitor MS 
cognitive performance [131]. The BICAMS, which does not require expert skills to 
administer, includes two memory tests (verbal and visual, respectively) besides the SDMT. 
The findings in the present thesis also suggest that inclusion of relevant moderating variables 
would improve the interpretation of cognitive outcomes following DMT interventions. 
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8 POPULÄRVETENSKAPLIG SAMMANFATTNING PÅ 
SVENSKA 
Den övergripande problemställningen i denna avhandling är kognitiv nedsättning vid multipel 
skleros (MS). MS är en kronisk sjukdom som drabbar unga vuxna, företrädesvis i åldern 20-
40 år med övervikt för kvinnor. I Sverige finns ca 18 000 personer med MS. Vid sjukdomen 
uppträder återkommande lokaliserade inflammationer (”plack”) inom centrala nervsystemet 
vilka kan ge upphov till en rad olika neurologiska symptom såsom gång-, kraft-, känsel- och 
synstörningar. En stor andel av MS-patienterna drabbas även av försämrade kognitiva 
funktioner. Särskilt ses nedsättning inom processhastighet, minne, uppmärksamhet och 
flexibilitets- och organisationsförmåga. MS-patienter med kognitiva problem har en ökad risk 
för arbetslöshet och sämre yrkeskarriär, sämre följsamhet mot ordinerad behandling och 
sämre upplevd livskvalitet. Inom den största MS-gruppen med s.k. skovvis förlöpande MS 
(relapsing-remitting MS, RRMS), uppskattas betydande kognitionssnedsättning föreligga hos 
mellan 22-40%.  
Frågeställningarna i avhandlingens delarbeten I-III var: Vilka faktorer och sjukdomsuttryck 
kan öka risken för att utveckla kognitiv nedsättning vid RRMS? Är det hur länge man haft 
sjukdomen, grad av neurologiska bortfall, försämringstakten, grad av depression eller abnorm 
uttröttbarhet (s.k. fatigue) som är av störst betydelse?  
De första delarbetena baseras på en tvärsnittsstudie av patienter med RRMS (n=72) och friska 
kontrollpersoner (n=89). Patienterna undersöktes kliniskt och fick besvara en rad 
frågeformulär. Patienter och friska undersöktes med ett kognitivt testbatteri. Hos patienterna 
var prestationen signifikant sämre jämfört med de friska. Som förväntat hade patienterna 
också betydligt högre förekomst av depression och fatigue än de friska kontrollerna. 
Analysen visade att depressionssymptom, ensamt eller i kombination med neurologiska 
bortfallssymptom, var de starkaste riskfaktorerna för kognitiv försämring vid RRMS. 
Betydelsen av depressionssymptomen var ännu tydligare om man exkluderade de symptom 
som berör kroppsliga depressionsuttryck (t.ex. dålig sömn och oro för sitt hälsotillstånd), 
eftersom dessa kan vara uttryck för själva grundsjukdomen. Våra fynd är viktiga eftersom de 
belyser att depressionssymptom, även måttliga, är kognitivt betydelsefulla och bör 
uppmärksammas av behandlande läkare.  
Deltagarna testades också med s.k. event-related potentials (ERP) som är en EEG-metod, och 
samtidigt mättes reaktionstiden. I synnerhet studerade vi styrkan i en specifik ERP-signal 
(P300). Vi fann att sambandet mellan P300 och kognitiv prestationsförmåga var betydligt 
starkare i patientgruppen jämfört med friska kontroller. Samma mönster sågs vad gällde 
reaktionstiden. Detta betyder att patienter som har, eller förmår upprätthålla, en starkare 
hjärnsignal (eller snabbare reaktionstid) var betydligt mindre benägna att uppvisa kognitiv 
nedsättning. Detta vittnar om att det finns en fysiologisk kognitiv reservkapacitet som 
utnyttjas vid RRMS, som kan förhindra eller minimera kognitiv försämring. 
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Kognitiva reservmekanismer har studerats tidigare, framför allt inom demensforskningen. 
Medfödda eller förvärvade faktorer har i viss utsträckning visats kunna skydda personers 
kognitiva funktioner i händelse av en sjukdom som drabbar hjärnan. Hög utbildningsnivå och 
god s.k. vokabulär kunskap har ansetts vara en sådan faktor, även vid MS. Vi testade denna 
hypotes på vårt studiematerial. I sådana jämförelser måste man ta hänsyn till att dessa 
faktorer även påverkar testresultatet hos friska försökspersoner, och testdata måste korrigeras 
därefter. Vi fann att patienter med högre utbildning och god vokabulär inte hade en mindre 
grad av kognitiv nedsättning jämfört de patienter som hade lägre utbildning. Hög utbildning 
och vokabulär kunskap utgjorde därmed ingen kognitiv reserv vid RRMS. Detta till skillnad 
från hög P300 amplitud och snabb reaktionstid som alltså uppvisade de kännetecken som 
karaktäriserar en kognitiv reserv. P300 och reaktionstiden kunde i våra beräkningar förklara 
en stor del av risken att utveckla kognitiv nedsättning vid RRMS. Denna reserv har tidigare 
inte beskrivits inom MS och kan komma att förbättra möjligheterna att identifiera MS-
patienter med högre respektive lägre risk för kognitiv svikt.  
Många s.k. bromsmediciner finns idag för behandling av RRMS. En vanlig 
förstahandsbehandling vid RRMS är interferon-beta men flera alternativ har tillkommit under 
de senaste åren och som inkluderar behandlingar som i mycket hög utsträckning minskar den 
inflammatoriska komponenten i sjukdomen. Det har emellertid gjorts få studier som specifikt 
utvärderar dessa läkemedels effekter på de kognitiva förmågorna. En av de mest effektiva 
bromsmedicinerna är natalizumab (NZ). Vår hypotes i delarbete IV var att NZ-behandling 
kunde motverka eller reversera kognitiv försämring vid RRMS. Vi genomförde en 
longitudinell studie där en grupp RRMS-patienter (n=15) som startade NZ-behandling 
jämfördes med stabila patienter på förstahandsbehandling (n=15) samt friska kontrollpersoner 
(n=12). Alla tre grupper testades kognitivt två gånger med ett års mellanrum. I båda MS-
grupperna, och i viss utsträckning även också hos de friska kontrollerna, sågs signifikanta 
förbättringar efter ett år. NZ-behandlade patienter förbättrades inte mer än den andra MS-
gruppen. Vi drog slutsatsen att de förbättrade kognitiva testresultaten var s.k. 
inlärningseffekter. Vi fann också att inlärningseffekten var starkare hos individer med ett 
sämre första resultat. Tidigare kognitionsstudier på NZ har sällan inkluderat kontrollgrupper 
och därmed inte observerat denna effekt. Vår slutsats är att NZ inte ger en mätbar kognitiv 
förbättring efter ett års behandling. Framtida behandlingsstudier bör ha noggrant definierade 
kontrollgrupper, beakta normala inlärningseffekter, löpa över längre tid samt med fördel även 
inkludera uppskattningar av deltagarnas kognitiva reservkapacitet. 
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